rs587779272
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_000179.3(MSH6):c.3563G>A(p.Ser1188Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000661 in 151,366 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
MSH6
NM_000179.3 missense
NM_000179.3 missense
Scores
14
4
1
Clinical Significance
Conservation
PhyloP100: 9.36
Genes affected
MSH6 (HGNC:7329): (mutS homolog 6) This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described. [provided by RefSeq, Jul 2013]
FBXO11 (HGNC:13590): (F-box protein 11) This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. It can function as an arginine methyltransferase that symmetrically dimethylates arginine residues, and it acts as an adaptor protein to mediate the neddylation of p53, which leads to the suppression of p53 function. This gene is known to be down-regulated in melanocytes from patients with vitiligo, a skin disorder that results in depigmentation. Polymorphisms in this gene are associated with chronic otitis media with effusion and recurrent otitis media (COME/ROM), a hearing loss disorder, and the knockout of the homologous mouse gene results in the deaf mouse mutant Jeff (Jf), a single gene model of otitis media. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jun 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.986
PP5
Variant 2-47805624-G-A is Pathogenic according to our data. Variant chr2-47805624-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 89421.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=5, Likely_pathogenic=3}. Variant chr2-47805624-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH6 | NM_000179.3 | c.3563G>A | p.Ser1188Asn | missense_variant | 7/10 | ENST00000234420.11 | NP_000170.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH6 | ENST00000234420.11 | c.3563G>A | p.Ser1188Asn | missense_variant | 7/10 | 1 | NM_000179.3 | ENSP00000234420.5 |
Frequencies
GnomAD3 genomes AF: 0.00000661 AC: 1AN: 151366Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
1
AN:
151366
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1451214Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 722506
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1451214
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
722506
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000661 AC: 1AN: 151366Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 73864
GnomAD4 genome
AF:
AC:
1
AN:
151366
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
73864
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 26, 2023 | Published functional studies demonstrate a damaging effect: deficient MMR activity (PMID: 21431882, 31965077); Observed in patients with Lynch-related cancers and tumor studies consistent with pathogenic variants in this gene (PMID: 21431882, 22495361); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22495361, 23621914, 17101317, 21431882, 30798936, 31965077, 34445333, 17531815, 21120944) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 04, 2021 | The variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, this variant has been reported in an individual with colorectal cancer (PMID: 17101317 (2006)). It has also been reported in a Lynch syndrome family where affected individuals were also positive for the MSH2 c.2768T>A (p.Val923Glu) variant (PMID: 21431882 (2011)). In addition, in vitro functional studies have shown that this variant has a deleterious effect on MSH6 protein function (PMIDs: 21431882 (2011), 31965077 (2020)). Based on the available information, this variant is predicted to be likely pathogenic. - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 11, 2021 | This missense variant replaces serine with asparagine at codon 1188 of the MSH6 protein. Computational prediction tool suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold ≥0.7, PMID: 27666373). Functional studies reported this variant as having deficient in vitro DNA repair activity (PMID: 21431882, 31965077). This variant has been reported in individuals suspected of having Lynch syndrome (PMID: 17101317, 21431882, 22495361). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 04, 2024 | The p.S1188N variant (also known as c.3563G>A), located in coding exon 7 of the MSH6 gene, results from a G to A substitution at nucleotide position 3563. The serine at codon 1188 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been previously reported in a family meeting Amsterdam criteria for HNPCC/Lynch syndrome and two affected family members that tested positive for this variant had abnormal, but inconsistent immunohistochemistry (IHC) results. In their colorectal tumors, one individual showed high microsatellite instability (MSI-H), absent MSH6, and reduced MSH2 protein expression while the other showed absent MSH2 with reduced MSH6 protein expression (MSI was not determined). Additionally, the family members who carry the MSH6 p.S1188N alteration also carry a variant of uncertain significance in MSH2 (Okkels H et al. Appl. Immunohistochem. Mol. Morphol. 2012 Oct;20:470-7; Kantelinen J et al. Fam. Cancer. 2011 Sep;10:515-20; Ollila S et al. Gastroenterology. 2006 Nov;131:1408-17). In an in vitro functional assay, MSH6 p.S1188N was reported to be completely deficient in mismatch repair compared to wild type (Kantelinen J et al. Fam. Cancer. 2011 Sep;10:515-20). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. - |
Lynch syndrome 5 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Aug 24, 2023 | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 21431882, 31965077]. This variant is expected to disrupt protein structure [Myriad internal data]. - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Aug 06, 2024 | This missense variant replaces serine with asparagine at codon 1188 of the MSH6 protein. Computational prediction tool suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >=0.7, PMID: 27666373). Functional studies reported this variant causing deficient in vitro DNA repair activity (PMID: 21431882, 31965077). This variant has been reported in individuals affected with Lynch syndrome-associated disease, and some individual's colorectal cancer tumors were confirmed to display high microsatellite instability and/or loss of MSH6 protein expression via immunohistochemistry analysis (PMID: 17101317, 21431882, 22495361; ClinVar SCV000813288.6). The c.2768T>A, p.V923E variant in the MSH2 gene was also reported in the related individuals affected with colorectal cancer (PMID: 17101317, 21431882, 22495361). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may be associated with disease, additional clinical studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1188 of the MSH6 protein (p.Ser1188Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with colorectal cancer (PMID: 21431882, 22495361; Invitae). ClinVar contains an entry for this variant (Variation ID: 89421). An algorithm developed specifically for the MSH6 gene suggests that this missense change is likely to be deleterious (PMID: 23621914). Experimental studies have shown that this missense change affects MSH6 function (PMID: 21431882, 31965077). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Endometrial carcinoma Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 28, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
.;.;D;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
.;.;.;H;.
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
.;D;.;D;D
REVEL
Pathogenic
Sift
Pathogenic
.;D;.;D;D
Sift4G
Pathogenic
D;D;D;D;D
Polyphen
1.0
.;.;.;D;.
Vest4
MutPred
0.97
.;.;.;Loss of catalytic residue at S1188 (P = 0.0658);.;
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at